John Despain, MD
Dermatology · Osage Beach, MONPI 1932196433
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $229,534 of the $289,300 with a category attached, or 79.3%. Amgen accounts for 70.8% of it on its own, with 35 other manufacturers making up the rest. Among dermatology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 914 payments — averaging $316.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$205K
- Bristol Myers Squibb$50K
- Galderma Laboratories, L.p.$8K
- AbbVie$5K
- E.r. Squibb & Sons, L.L.C.$4K
- Sun Pharmaceutical Industries Inc.$3K
- plus $14K from 30 others
Across 18 payments — averaging $2921.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$37K
- Almirall LLC$16K
What the payments were for
- Consulting fees$18,6236%
- Speaking & faculty fees$229,53479%
- Travel & lodging$21,8538%
- Food & beverage$18,7866%
- Education$5050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 215 | $204,859 |
| Bristol Myers Squibb | 51 | $50,302 |
| Galderma Laboratories, L.p. | 26 | $7,551 |
| AbbVie | 127 | $5,446 |
| E.r. Squibb & Sons, L.L.C. | 37 | $4,213 |
| Sun Pharmaceutical Industries Inc. | 43 | $3,128 |
| Regeneron Healthcare Solutions, Inc. | 36 | $2,850 |
| Genentech USA, Inc. | 25 | $2,302 |
| Almirall LLC | 20 | $1,267 |
| Johnson & Johnson | 55 | $1,266 |
| Lilly USA, LLC | 40 | $739 |
| Dermavant Sciences, Inc. | 29 | $709 |
| LEO Pharma Inc. | 28 | $660 |
| Pfizer | 27 | $641 |
| UCB, Inc. | 28 | $593 |
| Novartis | 25 | $448 |
| Sanofi | 20 | $377 |
| Janssen Scientific Affairs, LLC | 3 | $273 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 13 | $247 |
| Mayne Pharma Commercial LLC | 14 | $216 |
| Arcutis Biotherapeutics, Inc. | 9 | $201 |
| Biofrontera Inc. | 6 | $180 |
| Incyte Corporation | 8 | $159 |
| EPI Health, LLC | 6 | $106 |
| Kyowa Kirin, Inc. | 1 | $90 |
| Dermira, Inc. | 5 | $90 |
| DUSA Pharmaceuticals, Inc. | 1 | $87 |
| Novo Nordisk | 1 | $74 |
| Journey Medical Corporation | 3 | $54 |
| VYNE Pharmaceuticals Inc. | 3 | $47 |
| GRT US Holding, Inc. | 2 | $29 |
| Aclaris Therapeutics, Inc. | 1 | $23 |
| Pierre Fabre Pharmaceuticals, Inc. | 3 | $22 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $20 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $17 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$289,300 in reported general payments places this provider in the 95th percentile of 263 dermatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 15 | $154,826 |
| Dupixent PenDupilumab | 24 | $95,904 |
| OtezlaApremilast | 16 | $75,527 |
| XolairOmalizumab | 13 | $50,965 |
| Clobetasol Propionate | 76 | $4,773 |
| Ketoconazole | 219 | $3,567 |
| Doxycycline Hyclate | 107 | $2,711 |
| Metronidazole | 43 | $2,457 |
| Minocycline Hcl | 75 | $2,406 |
| Clindamycin Phosphate | 66 | $1,792 |
| Triamcinolone Acetonide | 175 | $1,732 |
| Calcipotriene | 16 | $1,621 |
| Fluocinonide | 42 | $1,620 |
| Pentoxifylline | 45 | $1,345 |
| Tacrolimus | 19 | $1,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $204,859 | $75,52716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 263 dermatology providers in Missouri.
Other dermatology in Osage Beach
- Brian KimSaint Louis$861K
- Elaine SiegfriedSaint Louis$856K
- Craig LeonardiSaint Louis$569K
- Jonathan CleaverKirksville$483K
- Mary GeorgeSaint Louis$400K
- David CleaverKirksville$371K
- Christy RaineyBranson$328K
- Charles MoonCape Girardeau$296K
- Duane DilworthSaint Louis$288K
- Murphy MastinBolivar$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.